PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

2.1 Preface
2.2 Preface
2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

Market ecosystem
Market characteristics
Market segmentation analysis

PART 04: MARKET SIZING

Market definition
Market sizing 2018
Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

Bargaining power of buyers
Bargaining power of suppliers
Threat of new entrants
Threat of substitutes
Threat of rivalry
Market condition

PART 06: MARKET SEGMENTATION BY PRODUCT

Market segmentation by product
Comparison by product
Dabrafenib - Market size and forecast 2018-2023
Sorafenib - Market size and forecast 2018-2023
Vemurafenib - Market size and forecast 2018-2023
Encorafenib - Market size and forecast 2018-2023
Market opportunity by product

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

Geographic segmentation
Geographic comparison
North America - Market size and forecast 2018-2023
Europe - Market size and forecast 2018-2023
Asia - Market size and forecast 2018-2023
ROW - Market size and forecast 2018-2023
Key leading countries
Market opportunity

PART 09: DRIVERS AND CHALLENGES

Market drivers
Market challenges

PART 10: MARKET TRENDS

PART 11: VENDOR LANDSCAPE

Overview
Landscape disruption
Competitive scenario

PART 12: VENDOR ANALYSIS

Vendors covered
Vendor classification
Market positioning of vendors
Array BioPharma Inc.
Bayer AG
F. Hoffmann-La Roche Ltd.
Novartis AG

PART 13: APPENDIX

Research methodology
List of abbreviations
Definition of market positioning of vendors

List of Exhibits
Exhibit 01: Global pharmaceuticals market
Exhibit 02: Segments of global pharmaceuticals market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition - Inclusions and exclusions checklist
Exhibit 06: Market size 2018
Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 09: Five forces analysis 2018
Exhibit 10: Five forces analysis 2023
Exhibit 11: Bargaining power of buyers
Exhibit 12: Bargaining power of suppliers
Exhibit 13: Threat of new entrants
Exhibit 14: Threat of substitutes
Exhibit 15: Threat of rivalry
Exhibit 16: Market condition - Five forces 2018
Exhibit 17: Product - Market share 2018-2023 (%)
Exhibit 18: Comparison by product
Exhibit 19: Dabrafenib - Market size and forecast 2018-2023 ($ millions)
Exhibit 20: Dabrafenib - Year-over-year growth 2019-2023 (%)
Exhibit 21: Sorafenib - Market size and forecast 2018-2023 ($ millions)
Exhibit 22: Sales data of sorafenib
Exhibit 23: Sorafenib - Year-over-year growth 2019-2023 (%)
Exhibit 24: Vemurafenib - Market size and forecast 2018-2023 ($ millions)
Exhibit 25: Vemurafenib - Year-over-year growth 2019-2023 (%)
Exhibit 26: Encorafenib - Market size and forecast 2018-2023 ($ millions)
Exhibit 27: Encorafenib - Year-over-year growth 2019-2023 (%)
Exhibit 28: Market opportunity by product
Exhibit 29: Customer landscape
Exhibit 30: Market share by geography 2018-2023 (%)
Exhibit 31: Geographic comparison
Exhibit 32: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 33: North America - Year-over-year growth 2019-2023 (%)
Exhibit 34: Top 3 countries in North America
Exhibit 35: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 36: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 37: Top 3 countries in Europe
Exhibit 38: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 39: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 40: Top 3 countries in Asia
Exhibit 41: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 42: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 43: Top 3 countries in ROW
Exhibit 44: Key leading countries
Exhibit 45: Market opportunity
Exhibit 46: Patient assistance programs
Exhibit 47: New cases of cancer in the US 2015
Exhibit 48: Alternative therapies based on BRAF kinase inhibitors for various oncology indications
Exhibit 49: Side effects of BRAF kinase inhibitors
Exhibit 50: Impact of drivers and challenges
Exhibit 51: Approved drugs with respect to their cancer indications
Exhibit 52: Expansion of research areas of BRAF kinase inhibitors
Exhibit 53: Strategic alliances in global BRAF kinase inhibitors market
Exhibit 54: Vendor landscape
Exhibit 55: Landscape disruption
Exhibit 56: Vendors covered
Exhibit 57: Vendor classification
Exhibit 58: Market positioning of vendors
Exhibit 59: Array BioPharma Inc. - Vendor overview
Exhibit 60: Array BioPharma Inc. - Business segments
Exhibit 61: Array BioPharma Inc. - Organizational developments
Exhibit 62: Array BioPharma Inc. - Geographic focus
Exhibit 63: Array BioPharma Inc. - Key offerings
Exhibit 64: Array BioPharma Inc. - Key customers
Exhibit 65: Bayer AG - Vendor overview
Exhibit 66: Bayer AG - Business segments
Exhibit 67: Bayer AG - Organizational developments
Exhibit 68: Bayer AG - Geographic focus
Exhibit 69: Bayer AG - Segment focus
Exhibit 70: Bayer AG - Key offerings
Exhibit 71: Bayer AG - Key customers
Exhibit 72: F. Hoffmann-La Roche Ltd. - Vendor overview
Exhibit 73: F. Hoffmann-La Roche Ltd. - Business segments
Exhibit 74: F. Hoffmann-La Roche Ltd. - Organizational developments
Exhibit 75: F. Hoffmann-La Roche Ltd. - Geographic focus
Exhibit 76: F. Hoffmann-La Roche Ltd. - Segment focus
Exhibit 77: F. Hoffmann-La Roche Ltd. - Key offerings
Exhibit 78: F. Hoffmann-La Roche Ltd. - Key customers
Exhibit 79: Novartis AG - Vendor overview
Exhibit 80: Novartis AG - Business segments
Exhibit 81: Novartis AG - Organizational developments
Exhibit 82: Novartis AG - Geographic focus
Exhibit 83: Novartis AG - Segment focus
Exhibit 84: Novartis AG - Key offerings
Exhibit 85: Novartis AG - Key customers
Exhibit 86: Validation techniques employed for market sizing
Exhibit 87: Definition of market positioning of vendors

Companies Mentioned

. BorgWarner Inc.
. Continental AG
. Eaton
. JTEKT Corp.
. Robert Bosch GmbH
. ZF Friedrichshafen AG